21 April 2022>: Articles
A Case Report of a 58-Year-Old Woman with a Diagnosis of High-Risk Myeloma Refractory to Multiple Line of Therapy and Treated with Selinexor, Bortezomib, and Dexamethasone Prior to Allogeneic Stem Cell Transplantation
Unusual clinical course, Unusual or unexpected effect of treatment
Michael Cass A* , Andrew B. McDonald B , Osnat Ben-Shahar D , Yosef Landesman C , Trinayan Kashyap CDOI: 10.12659/AJCR.935353
Am J Case Rep 2022; 23:e935353
Figure 1. Timeline of treatments given to the patient between diagnosis and until commencing treatment with selinexor. ASCT – autologous stem cell transplantation; CR – complete response; CTD – cyclophosphamide, thalidomide, dexamethasone; DCEP – dexamethasone, cyclophosphamide, etoposide, cisplatin; HDM – high-dose melphalan; ICd – ixazomib, cyclophosphamide, prednisone; IRd – ixazomib, lenalidomide, dexamethasone; PAD – bortezomib, doxorubicin, dexamethasone; Pom/Dex – pomalidomide, dexamethasone; PD – progressive disease; PR – partial response; SD – stable disease; XVd – selinexor, bortezomib, dexamethasone; VAD – vincristine, doxorubicin, dexamethasone; VGPR – very good partial response.